Clinical Trials Directory

Trials / Conditions / Unresectable Metastatic Colorectal Cancer

Unresectable Metastatic Colorectal Cancer

12 registered clinical trials studyying Unresectable Metastatic Colorectal Cancer6 currently recruiting.

StatusTrialSponsorPhase
RecruitingFirst-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastat
NCT06934538
Brenus PharmaPhase 1 / Phase 2
Not Yet RecruitingSBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresect
NCT06835179
The First Affiliated Hospital with Nanjing Medical UniversityPhase 2
Not Yet RecruitingBevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment
NCT06642844
University Hospital, ToursPhase 3
Active Not RecruitingStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receivi
NCT06107413
AbbViePhase 2
RecruitingFruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-
NCT06148402
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPhase 2
UnknownA Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Co
NCT04866108
Beijing Friendship HospitalPhase 2
RecruitingStudy of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
NCT04991948
Celyad Oncology SAPhase 1
UnknownA Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (Cape
NCT05068206
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2
UnknownProbiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Ca
NCT04131803
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityN/A
UnknownmXELOXIRI Combined With Molecular Targeted Drug in mCRC
NCT04160416
First Affiliated Hospital of Zhejiang UniversityPhase 2
RecruitingalloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Ant
NCT03692429
Celyad Oncology SAPhase 1
CompletedOPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer
NCT01802684
GERCOR - Multidisciplinary Oncology Cooperative GroupPhase 2